COCP
Cocrystal Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.19
+4.39%Sep 9, 2026, 14:30 UTC
Cocrystal Pharma announced that the last subject has been dosed in its Phase 1b human challenge study evaluating CDI-988 as a potential preventive and treatment for norovirus infection.
Source:Aug 18, 2026, 00:00 UTC
Cocrystal Pharma, Inc. appointed Carol L. Brosgart as a director of the Company, effective August 12, 2026.
Aug 3, 2026, 11:00 UTC
Cocrystal Pharma announced a $5 million private placement with OPKO Health, which increased its investment in the company.
Source:Jun 9, 2026, 00:00 UTC
Cocrystal Pharma, Inc. appointed James Sapirstein as Chief Executive Officer effective June 3, 2026.